Anticoagulants and thrombolytics during pregnancy

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Pharmacology

Background:

• Venous thromboembolism (VTE) is a rare but serious pregnancy complication and a leading cause of maternal mortality.
• A significant percentage of pregnant women with deep venous thrombosis (DVT) may have an undiagnosed pulmonary embolism (PE).
• Certain risk factors necessitate anticoagulant therapy during pregnancy, including mechanical cardiac valve prostheses and deficiencies in antithrombin, protein C, or protein S.

Purpose of the Study:

• To discuss the appropriate use of anticoagulants and thrombolytics in pregnant women.
• To highlight the importance of individualized treatment selection based on specific conditions.
• To address the risks associated with anticoagulant therapy for both mother and fetus.

Main Methods:

• Review of current literature on anticoagulant and thrombolytic use in pregnancy.
• Analysis of risk factors and indications for anticoagulation.
• Discussion of therapeutic choices, dosages, and durations.

Main Results:

• Anticoagulant therapy is indicated for pregnant women with VTE, a history of VTE, or specific high-risk conditions.
• Treatment selection, dosage, and duration must be tailored to the individual patient's condition.
• Anticoagulant therapy presents risks to both the mother and the developing fetus.

Conclusions:

• Careful consideration and individualized management are crucial for anticoagulation in pregnancy.
• Balancing the benefits of preventing VTE against potential risks is essential.
• Further research may be needed to optimize safety and efficacy of these treatments in obstetric patients.